BACKGROUND: Highly pathogenic avian influenza A(H5N1) causes severe infections in humans. We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLAIVs), but they failed to elicit a primary immune response. Our objective was to determine whether the vaccines primed or established long-lasting immunity that could be detected by administration of inactivated subvirion influenza A(H5N1) vaccine (ISIV). METHODS: The following groups were invited to participate in the study: persons who previously received influenza A(H5N1) pLAIV; persons who previously received anirrelevant influenza A(H7N3) pLAIV; and community members who were naive to influenza A(H5N1) and LAIV. LAIV-experienced subjects received a single 45-μg dose of influenza A(H5N1) ISIV. Influenza A(H5N1)- and LAIV-naive subjects received either 1 or 2 doses of ISIV. RESULTS: In subjects who had previously received antigenically matched influenza A(H5N1) pLAIV followed by 1 dose of ISIV compared with those who were naive to influenza A(H5N1) and LAIV and received 2 doses of ISIV, we observed an increased frequency of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly higher antibody titer (112 vs 76; P = .04). The affinity of antibody and breadth of cross-clade neutralization was also enhanced in influenza A(H5N1) pLAIV-primed subjects. CONCLUSIONS: ISIV administration unmasked long-lasting immunity in influenza A(H5N1) pLAIV recipients, with a rapid, high-titer, high-quality antibody response that was broadly cross-reactive across several influenza A(H5N1) clades. CLINICAL TRIALS REGISTRATION: NCT01109329. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: Highly pathogenic avian influenza A(H5N1) causes severe infections in humans. We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLAIVs), but they failed to elicit a primary immune response. Our objective was to determine whether the vaccines primed or established long-lasting immunity that could be detected by administration of inactivated subvirion influenza A(H5N1) vaccine (ISIV). METHODS: The following groups were invited to participate in the study: persons who previously received influenza A(H5N1) pLAIV; persons who previously received an irrelevant influenza A(H7N3) pLAIV; and community members who were naive to influenza A(H5N1) and LAIV. LAIV-experienced subjects received a single 45-μg dose of influenza A(H5N1) ISIV. Influenza A(H5N1)- and LAIV-naive subjects received either 1 or 2 doses of ISIV. RESULTS: In subjects who had previously received antigenically matched influenza A(H5N1) pLAIV followed by 1 dose of ISIV compared with those who were naive to influenza A(H5N1) and LAIV and received 2 doses of ISIV, we observed an increased frequency of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly higher antibody titer (112 vs 76; P = .04). The affinity of antibody and breadth of cross-clade neutralization was also enhanced in influenza A(H5N1) pLAIV-primed subjects. CONCLUSIONS: ISIV administration unmasked long-lasting immunity in influenza A(H5N1) pLAIV recipients, with a rapid, high-titer, high-quality antibody response that was broadly cross-reactive across several influenza A(H5N1) clades. CLINICAL TRIALS REGISTRATION: NCT01109329. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
H5N1; avian influenza; live attenuated; vaccine
Authors: J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz Journal: Vaccine Date: 2001-02-08 Impact factor: 3.641
Authors: R B Belshe; W C Gruber; P M Mendelman; I Cho; K Reisinger; S L Block; J Wittes; D Iacuzio; P Piedra; J Treanor; J King; K Kotloff; D I Bernstein; F G Hayden; K Zangwill; L Yan; M Wolff Journal: J Pediatr Date: 2000-02 Impact factor: 4.406
Authors: Iain Stephenson; Karl G Nicholson; Anthony Colegate; Audino Podda; John Wood; Ellen Ypma; Maria Zambon Journal: Vaccine Date: 2003-04-02 Impact factor: 3.641
Authors: Paul M Mendelman; Ruth Rappaport; Iksung Cho; Stan Block; William Gruber; Marilyn August; Denise Dawson; Julie Cordova; George Kemble; Kutubuddin Mahmood; Giuseppe Palladino; Min-Shi Lee; Ahmad Razmpour; Jeffrey Stoddard; Bruce D Forrest Journal: Pediatr Infect Dis J Date: 2004-11 Impact factor: 2.129
Authors: K Subbarao; A Klimov; J Katz; H Regnery; W Lim; H Hall; M Perdue; D Swayne; C Bender; J Huang; M Hemphill; T Rowe; M Shaw; X Xu; K Fukuda; N Cox Journal: Science Date: 1998-01-16 Impact factor: 47.728
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao Journal: PLoS Med Date: 2006-09 Impact factor: 11.069
Authors: Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz Journal: Vaccine Date: 2015-10-23 Impact factor: 3.641
Authors: Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer Journal: Nat Med Date: 2020-12-07 Impact factor: 53.440
Authors: Kenta Matsuda; Stephen A Migueles; Jinghe Huang; Lyuba Bolkhovitinov; Sarah Stuccio; Trevor Griesman; Alyssa A Pullano; Byong H Kang; Elise Ishida; Matthew Zimmerman; Neena Kashyap; Kelly M Martins; Daniel Stadlbauer; Jessica Pederson; Andy Patamawenu; Nathaniel Wright; Tulley Shofner; Sean Evans; C Jason Liang; Julián Candia; Angelique Biancotto; Giovanna Fantoni; April Poole; Jon Smith; Jeff Alexander; Marc Gurwith; Florian Krammer; Mark Connors Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel Journal: Nat Med Date: 2016-10-31 Impact factor: 53.440